August 11, 2026

Second Quarter 2026 Financial Results & Corporate Update

This presentation is for investor relations purposes only - Not for product promotional purposes

Agenda

1. Opening Remarks
2. Q2 2026 Highlights & Recent Accomplishments
3. Pipeline
4. CARVYKTI® Performance Overview
5. Financial Performance
6. Q&A

Alan Bash

Interim Chief Executive Officer

Carlos Santos

Chief Financial Officer

LEGEND BIOTECH

Forward-looking Statements

This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Company.

The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not been established, except to the extent specifically provided by marketing authorizations previously received from relevant health authorities. Further, for investigational agents and/or uses, the Company cannot guarantee health authority approval or that such agents and/or uses will become commercially available in any country.

Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Legend Biotech's own internal estimates and research. While Legend Biotech believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Legend Biotech believes its internal research is reliable, such research has not been verified by any independent source.

Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995.

These statements include, but are not limited to, statements relating to Legend Biotech's strategies and objectives; statements relating to CARVYKTI® (ciltacabtagene autoleucel; cilta-cel), including patient population of CARVYKTI®, Legend Biotech's expectations for CARVYKTI®, including manufacturing expectations for CARVYKTI®; and statements about regulatory submissions for CARVYKTI®, statements related to Legend Biotech's ability to achieve operating profit; statements related to Legend Biotech's ability to fund its operations beyond 2026 and Legend Biotech's anticipated profitability in 2026; the progress of submissions with the FDA, the EMA and other regulatory authorities; expected results and timing of clinical trials; Legend Biotech's expectations on advancing its pipeline and product portfolio, and the potential benefits of Legend Biotech's product candidates, including the potential of LB2102 and LB2501 and the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech's patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the "Risk Factors" section of Legend Biotech's Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (SEC) on March 10, 2026 and Legend Biotech's other filings with the SEC.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this presentation as anticipated, believed, estimated or expected. Any forward-looking statements contained in this presentation speak only as of the date of this presentation. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

LEGEND BIOTECH

Non-IFRS financial metrics

This presentation refers to certain non-IFRS financial metrics.

We use Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Share (which we sometimes refer to as “Adjusted EPS”, or “ANI per Share”, respectively) as performance metrics. Adjusted Net Income (Loss) and ANI per Share are not defined under IFRS, are not a measure of operating income, operating performance, or liquidity presented in accordance with IFRS, and are subject to important limitations. Our use of Adjusted Net Income (Loss) has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under IFRS. For example: (i) although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted Net Income (Loss) does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements; (ii) Adjusted Net Income (Loss) excludes unrealized foreign exchange gain (loss); (iii) Adjusted Net Income (Loss) does not reflect changes in, or cash requirements for, our working capital needs; and (iv) Adjusted Net Income (Loss) excludes such as share based compensation expense, which has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy. Also, our definition of Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per share may not be the same as similarly titled measures used by other companies.

However, we believe that providing information concerning Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Share enhances an investor’s understanding of our financial performance. We use Adjusted Net Income (Loss) as a performance metric that guides management in its operations of planning for the future of the business. We believe that Adjusted Net Income (Loss) provides a useful measure of our operation performance from a period to period by excluding certain items that we believe are not representative of our core business. We define Adjusted Net Income (Loss) as Net Income (Loss) adjusted for (1) non-cash items such as depreciation and amortization, share-based compensation, and impairment loss and (2) unrealized foreign exchange gain (loss). Adjusted Net Income (Loss) per Share is computed by dividing Adjusted Net Income (Loss) by the weighted average shares outstanding.

Reconciliations of Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Share to the most directly comparable IFRS measures are included at the end of this presentation.

Alan Bash

Interim Chief Executive Officer

Q2 2026 Highlights & Recent Accomplishments

Q2 2026 Highlights

- CARVYKTI® Net Trade Sales grew 50% YoY[1] **$657M**
  - 32% YoY growth in US
  - 128% YoY growth OUS
- CARVYKTI® is launched in **19 global markets,** with 348[2] global activated CARVYKTI® treatment sites
- At EHA 2026, established first clinical proof-of-concept data for LB2501, *in vivo* CAR-T cell therapy for R/R B-NHL patients[3]
- At ASCO 2026, announced new CARTITUDE program data as well as first-in-human clinical data for LB2102, a DLL3-targeted CAR-T therapy for SCLC and LCNEC[4]
- Closed public offering of ADSs resulting in approximately $212 million of net proceeds

1. YoY = year over year 2. As of August 4, 2026. 3. Presented LB2501 results in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006) 4.Presented data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting (Abstract #8012) (Abstract #7536) (Abstract #7533)

CARVYKTI® Sales Highlights

Expanding market penetration and earlier-line adoption represent a substantial and durable growth opportunity



	YoY Growth[1]	QoQ Growth[2]
U.S.	32%	9%
OUS[3]	128%	13%
Global[4]	50%	10%

- U.S. QoQ growth of 9% primarily driven by:
  - Accelerated uptake in earlier treatment lines
  - ATCs[5] includes ~40% community hospitals
- OUS QoQ growth of 13% primarily driven by:
  - Launch uptake in 19 markets worldwide, with 196 OUS treatment sites

1. Q2 2026 vs Q2 2025; 2. Quarter over Quarter growth for Q2 2026 vs Q1 2026 ; 3. OUS – Outside U.S. 4. Includes a currency impact. Excluding the 1.7% YoY currency impact, global operational growth was 47.7% YoY; 5. ATC – Authorized Treatment Centers

Select Presentations at ASCO 2026

LB2102 & CARTITUDE Program Data

LB2102 - DLL3-targeted CAR-T therapy for SCLC[1] & LCNEC[2]

- At higher dose levels, LB2102 achieved an ORR[3] of 28.6% and a DCR[4] of 78.6%, with durable responses observed in some patients
- Demonstrated a manageable safety profile and encouraging clinical activity in heavily pretreated patients

CARTITUDE Program

- Continued to support durable efficacy and a consistent safety profile for CARVYKTI® in multiple myeloma, including sustained PFS/OS[5] benefit across cytogenetic risk groups and a low incidence (1.2%) of IEC-EC[6]

1. Small Cell Lung Cancer. 2. Large-cell Neuroendocrine Carcinoma. 3. Overall Response Rate 4. Disease Control Rate 5. Progression-Free Survival/Overall Survival 6. Immune Effector Cell-Associated Enterocolitis

LEGEND BIOTECH

Promising LB2501 Efficacy Data from EHA 2026

LB2501: *in vivo* CD19/CD20 dual-target CAR-T therapy
Phase 1 study in adults with Relapsed/Refractory B-Cell NHL

Response Rate	DL2 (N=6)	Total (N=12)
ORR, n (%) [95% CI]	6 (100) [54.1-100]	6 (50.0) [21.1-78.9]
CR, n (%) [95% CI]	5 (83.3) [35.9-99.6]	5 (41.7) [15.2-72.3]

Duration of Responses in Patients (DL2)



Pt 8 had prior TCE with washout of 2.7 months

RESULTS PRESENTED AT EHA[1] 2026

- Dose Level 2 (DL2) across DLBCL[2], MCL[3] and FL[4]:
  - **100% (6/6) ORR[5]**
  - **83.3% (5/6) CR[6]**
- CAR-T cells **detectable in peripheral blood for up to 116 days**
- LB2501 is well tolerated with no DLTs[7], SAEs[8], and no deaths

CLINICAL DEVELOPMENT PLANS

- Anticipate filing IND[9] for LB2501 in 2H 2026

1. EHA: European Hematology Association; 2. DLBCL: Diffuse Large B-Cell Lymphoma; 3. MCL: Mantle Cell Lymphoma; 4. FL: Follicular Lymphoma; 5. ORR: Objective Response Rate; 6. CR: Complete Response; 7. DLT: Dose-Limiting Toxicity; 8. Serious Adverse Events; 9. IND: Investigational New Drug application; 10. TCE: T-cells Engager

Advancing a Robust, Differentiated Cell Therapy Pipeline

Program	Target	Indication	Pre-Clinical / Phase I / Phase II / Phase III / NDA	Current Status	Partner
CARVYKTI®: BCMA-directed Autologous Therapy					
CARVYKTI®	BCMA	NDMM (Front-line) (Transplant Not Intended) (CARTITUDE-5)[1]	Multi-Regional Clinical Trial	*Patient follow-up*	Johnson&Johnson
		NDMM (Front-line, Transplant Eligible) (CARTITUDE-6)[1]	Multi-Regional Clinical Trial	*Patient follow-up*	
		NDMM (Front-line, Transplant Not Intended) (CARTITUDE-10)[1]	Multi-Regional Single Arm Trial	*Enrolling*	
Autologous Therapies					
LB1908	Claudin 18.2	Relapsed/Refractory Gastric & Pancreatic Cancers[3]	US IND	*Met primary endpoint, patient follow-up*	
LB2102	DLL3	2L+ Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma [3][4]	US IND	*Met primary endpoint, patient follow-up*	NOVARTIS
LB2401	GPRC5D	Relapsed/Refractory Multiple Myeloma[2]		*Patient follow-up*	
LB2402	CD19 x GPRC5D	Relapsed/Refractory Multiple Myeloma[2]		*Patient follow-up*	
LB2403	GPRC5D (FAST CAR)	Relapsed/Refractory Multiple Myeloma[2]		*Patient follow-up*	
LB2502	FcRH5 (FAST CAR)	Relapsed/Refractory Multiple Myeloma[2]		*Enrolling*	
Allogeneic Therapies					
LB2404D	CD19 x CD70 (CAR-γδ T)	Relapsed/Refractory Autoimmune Diseases[2]		*Enrolling*	
LB2405	CD19 x BCMA (CAR-NK)	Relapsed/Refractory Autoimmune Diseases[2]		*Enrolling*	
LB2302	CD20 (CAR-αβ T)	Relapsed/Refractory B-cell Non-Hodgkin Lymphoma[2]		*Enrolling*	
LB2303	CD19 x CD20 (CAR-γδ T)	Relapsed/Refractory B-cell Non-Hodgkin Lymphoma[2]		*Enrolling*	
LB2406	CD19 x CD20 (CAR-γδ T)	Relapsed/Refractory B-cell Non-Hodgkin Lymphoma[2]		*Enrolling*	
In Vivo Therapies					
LB2501	CD19 x CD20	Relapsed/Refractory B-cell Non-Hodgkin Lymphoma[2]		*Enrolling*	
LB2503	GPRC5D	Relapsed/Refractory Multiple Myeloma[2]		*Enrolling*	
LB2505	BCMA	Relapsed/Refractory Autoimmune Diseases[2]		*Initiating*	

Notes:
1. In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson. NDMM = Newly Diagnosed Multiple Myeloma.
2. Phase 1 investigator-initiated trial in China
3. IND applications have been cleared by the United States FDA
4. Subject to an exclusive license agreement with Novartis Pharma AG. The safety and efficacy of the agents and/or uses under investigation have not been established. There is no assurance that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. Additionally, as some programs are still confidential, certain candidates may not be included in this list

LEGEND BIOTECH

Well Positioned For Long-Term Growth

CARVYKTI® Profitable[1]

$657M
Q2 2026 CARVYKTI Net Trade Sales

~$965 Million
Cash Position[2]

14
Pipeline Programs

CAR-T Leadership in MM[3]

- CARVYKTI® is the top-selling CAR-T in a single quarter[4]
- >$5B peak annual sales potential[5]

Cell Therapy Innovation

- Advancing next generation cell therapy pipeline, with promising in vivo data presented at EHA 2026
- Expecting IND submission for LB2501 in 2H 2026

Durable Global Business

- ~$965 Million in Cash, Cash Equivalents and Time Deposits[2]
- Expect to achieve company-wide profitability in 2026[6]

~13,000 patients treated with CARVYKTI® [7]

1. Net Trade Sales - Cost of Good Sold - Operating Expenses = CARVYKTI Profit; 2. As of June 30, 2026; 3. MM = Multiple Myeloma; 4. For the quarter ended June 30, 2026; 5. Legend Biotech and Johson & Johnson Estimate; 6. Company-wide profit defined as Adjusted Net Income; 7. As of July 13 6, 2026

LEGEND BIOTECH

Carlos Santos

Chief Financial Officer

Progress Towards Sustainable Profitability in 2026

Strong underlying demand growth, with Operating Margin improving from -142% in 2Q23 to 15% in 2Q26





Revenue has scaled at a **CAGR of 74%** since 2Q23, with gradual gross margin improvements

CARVYKTI® franchise became profitable in 2025, expect company-wide profitability in 2026[1]

1. Company-wide profitability defined as Adjusted Net Income

Q2 2026 Financial Highlights

$ in millions (except per share)	Q2 2026	Q2 2025	Change
Collaboration Revenue	326.1	219.7	*48%*
License & Other Revenue	61.4	35.4	*73%*
Total Revenue	387.5	255.1	*52%*
Gross Margin on Net Product Sales	*58%*	*57%*	*1%*
Total Operating Expenses	192.4	179.0	*7%*
R&D	96.0	98.3	*-2%*
SG&A	96.4	80.7	*19%*
Operating Income (Loss)	57.7	(21.9)	*NMF[3]*
Income Tax	(22.3)	(0.6)	*NMF*
Net Income (Loss)	33.2	(125.4)	*NMF*
ANI[1] (Loss)[2]	63.1	10.1	*NMF*
ANI (Loss)[2] Per Share – Basic	$0.17	$0.03	*NMF*
ANI (Loss) Per Share – Diluted	$0.16	$0.03	*NMF*

Driving Operating Leverage Over Time

- Significant revenue growth of **52% YoY** with operating expenses growth of only **7% YoY**
- Gross margin improved **~150 bps YoY** driven by higher volume, labor utilization and OOS[4] improvement
- Lower R&D investment of **-2% YoY** primarily driven by BCMA[5] frontline clinical studies maturing
- SG&A investment **increased 19%** primarily due to emphasis on sustaining BCMA CAR-T market leadership while keeping G&A flat
- Operating margin of **15%** vs. **-9%** in 2Q25
- Incomes taxes of $22.3 million primarily driven by an increase in taxable income across our U.S., Belgium and PRC entities.
- ANI grew **more than 6x YoY** to $63.1 million

1. ANI: Adjusted Net Income. 2. Adjusted Net Loss and Adjusted Net Loss per Share (on basic and diluted shares basis) are non-IFRS measures. Reconciliations of Adjusted Net Loss and Adjusted Net Loss Per Share to the most directly comparable IFRS measures are included at the end of this presentation. The definitions of these non-IFRS measures are at the beginning of this presentation. 3. Not Meaningful. 4. OOS: Out of Spec. 5. BCMA – B-cell maturation antigen.

Profitability and Strong Balance Sheet for Business Sustainability

2026 Goals

- 3/4 of CARVYKTI® orders from 2-4L
- Consecutive quarter over quarter growth
- Company-wide profitability expected in 2026[1]
- IND submission for LB2501

Investment Priorities

- Advancing *in vivo* CAR-T pipeline programs
- Focused, synergistic business development
- Modest capital expenditures for ongoing manufacturing capacity expansion

Balance Sheet Strength

- ~$965 Million in Cash, Cash Equivalents and Time Deposits as of June 30, 2026
- No long-term debt

1. Company-wide profitability defined as Adjusted Net Income

LEGEND BIOTECH

Q&A

Alan Bash
Interim Chief Executive Officer

Carlos Santos
Chief Financial Officer

Yuhong Qiu
Interim Head of R&D

Thank you!

Reconciliation of IFRS to Non-IFRS Metrics

	Three months ended June 30,	
($ in millions, except per share data)	**2026**	**2025**
Net income (loss)	33.2	(125.4)
Depreciation and amortization	11.7	5.9
Share-based compensation	17.3	18.7
Impairment loss (included in other operating expense)	0.3	0
Unrealized foreign exchange loss/(gain) (included in Other income/(expense), net)	0.6	110.9
Adjusted net income (loss)	63.1	10.1
Adjusted net income (loss) per share:		
Adjusted net income (loss) per share – basic	0.17	0.03
Adjusted net income (loss) per share – diluted	0.16	0.03
Financials under IFRS		
Earnings (loss) per share – basic	0.09	(0.34)
Earnings (loss) per share – diluted	0.09	(0.34)